Gema Ariceta Iraola Institutions of which they are part Main researcher Kidney Physiopathology Vall Hebron Institut de Recerca Email Gema Ariceta Iraola Email Institutions of which they are part Main researcher Kidney Physiopathology Vall Hebron Institut de Recerca
Research lines Mechanisms of chronic renal disease progression and cardiovascular risk in pediatric patients with chronic renal disease Pediatric patients with chronic kidney disease (CKD) constitude a high risk group for cardiovascular disease (CVD) related to traditional and non-traditional risk factors. We are interested in studying the relationship between traditional CVD risk factors (obesity, overweight, anemia, dyslipemia, malnutrition, hypertension, and non-traditional CVD risk factors (homocysteine, asymmetric dymethylarginine (ADMA), FGF23, ultraselective protein C (PCR) and carotid intima-media thickness (cIMT) in children and adolescents with CKD, based on its severity and duration. Further, we are also interested in finding a biomarker to identify early in the disease, those patients with increased CVD risk and poor outcome. IP: Gema Ariceta Iraola Rare inhirited renal diseases Our group is focused in research in primary or inherited tubular renal diseases, such as Dent’s Disease, Bartter syndrome, Tubular Acidosis, Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis, among others. Currently we are collaborating with other groups in Spain, within a research project named Renaltube the main purpose of which is to build a database while facilitating access to genotyping in order to improve the clinical and molecular knowledge of primary tubulopathies. Renaltube has a web-based approach with multilateral collaboration scheme that enhances the recruitment of data and promotes the understanding of underlying mechanisms of rare inherited diseases, defines more accurate diagnostic and follow-up criteria, develops new molecular techniques and will improve the overall care of the patients. Currently we are offering the analysis of 22 genes corresponding to 23 primary tubulopathies. After two years of activity Renaltube has collected data from 222 patients, the mayority from Spain and Latin America (85.3%). The most common tubulopathies are distal renal tubular acidosis (22.5%), and classical Bartter syndrome (19.3%) followed by familial hypomagesemia with hipercalciuria and nephrocalcinosis (15.7%), and Gitelman syndrome (15%). IP: Gema Ariceta Iraola, Anna Meseguer Navarro Projects Biomarcadores, dianas y soluciones terapéuticas para mejorar el cuidado de pacientes afectados de Hipomagnesemia Familiar con Hipercalciuria y Nefrocalcinosis (HFHNC). IP: Gema Ariceta Iraola Collaborators: Hector Rios Duro, Mónica Durán Fernández, Gloria Mª Fraga Rodriguez , Julieta Torchia Funding agency: Instituto de Salud Carlos III Funding: 202070 Reference: PI22/01946 Duration: 01/01/2023 - 31/12/2025 NA IP: Anna Meseguer Navarro Collaborators: Gema Ariceta Iraola, Alejandro Cruz Gual, Gerard Cantero Recasens, David Lorente García, Marina Muñoz López, Mercedes López González, Hector Rios Duro, Mónica Durán Fernández, Luis Augusto Castro Sáder, Gloria Mª Fraga Rodriguez , Julieta Torchia Funding agency: AGAUR no fer servir-correcte 4301-37 Funding: 40000 Reference: 2021 SGR 01600 Duration: 01/01/2022 - 31/12/2024 ADQUISICIÓN DE UN MICROSCOPIO MULTIDIMENSIONAL WIDEFIELD EQUIPADO PARA REALIZAR EXPERIMENTOS IN VIVO, DESTINADO A LA PLATAFORMA DE MICROSCOPÍA DE LA UNIDAD DE ALTA TECNOLOGÍA (UAT) IP: Inmaculada Fuentes Camps Collaborators: Maria Vicario Perez, Soledad Gallego Melcón, Fco Javier Santos Vicente, Diego Arango Corro, Gema Ariceta Iraola, Santiago Ramon y Cajal Agüeras, Marta Martínez Vicente, Anna Meseguer Navarro, Manuel Comabella Lopez, Ricardo Pujol Borrell, Joan Sahuquillo Barris, Miguel Segura Ginard, Simon Schwartz Navarro, Anna Rosell Novel, Meritxell Genesca Ferrer Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 177204.2 Reference: EQC2019-006309-P Duration: 01/01/2019 - 31/12/2020 Identificación de biomarcadores y procesos moleculares que subyacen a la progresión de la enfermedad de Dent para el descubrimiento de nuevas dianes terapéuticas y desarrollo de fármacos in silico. IP: Anna Meseguer Navarro Collaborators: Gema Ariceta Iraola, Carla Burballa Tàrrega Funding agency: Sociedad Española de Nefrología (S.E.N.) Funding: 24000 Reference: SENEFRO/2019/MESEGUER Duration: 21/04/2020 - 20/04/2022 Pagination Current page 1 Page 2 Next page › Last page »
